Pre-surgery (neo adjuvant) trials (for patients before surgery to remove the kidney tumour)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (EA8143 PROSPER-RCC)  Nivolumab  III
 recruiting
National Cancer Institute (NCI) click here
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)  Nivolumab  II
 recruiting
Royal Marsden NHS Foundation Trust click here
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)  Pembrolizumab Pre-Resection, Pembrolizumab Post-Resection  I
 completed
Merck Sharp & Dohme Corp. click here

First line treatment (for patients who have not yet had any systemic therapy for advanced kidney cancer)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)  Nivolumab, Ipilimumab  IV
 active, not recruiting
Bristol-Myers Squibb click here
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)  Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo  III
 recruiting
Exelixis click here
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)  Cabozantinib, Sunitinib  III
 active, not recruiting
Bristol-Myers Squibb click here
An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer  Nivolumab, Ipilimumab  III
 recruiting
Bristol-Myers Squibb click here
Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer (PDIGREE)  Cabozantinib, Nivolumab, Ipilimumab  III
 recruiting
National Cancer Institute (NCI) click here
A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)  Cabozantinib, Sunitinib, NKTR-214  III
 recruiting
Nektar Therapeutics click here
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)  Standard Treatment  III
 terminated
Argos Therapeutics click here
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)  Sunitinib  III
 active, not recruiting
Bristol-Myers Squibb click here
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151)  Sunitinib, Bevacizumab, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody  III
 active, not recruiting
Hoffmann-La Roche click here
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)  Lenvatinib, Everolimus, Sunitinib, Pembrolizumab  III
 active, not recruiting
Eisai Inc. click here
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)  Sunitinib, Avelumab (MSB0010718C), Axitinib (AG-013736)  III
 active, not recruiting
Pfizer click here
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)  Sunitinib, Axitinib  III
 active, not recruiting
Merck Sharp & Dohme Corp. click here
Savolitinib vs. Sunitinib in MET-driven PRCC  Sunitinib, Savolitinib  III
 active, not recruiting
AstraZeneca click here
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:  Bevacizumab, MK-3475  I, II
 active, not recruiting
Arkadiusz Z. Dudek, MD click here
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer  Cabozantinib, Sunitinib, Savolitinib, Cabozantinib S-malate, Crizotinib, Sunitinib Malate  II
 recruiting
National Cancer Institute (NCI) click here
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma  Pazopanib + interferon alpha 2A  I, II
 active, not recruiting
Spanish Oncology Genito-Urinary Group click here
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800)  Nivolumab, Ipilimumab  II
 active, not recruiting
Bristol-Myers Squibb click here
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)  Nivolumab, Ipilimumab  II
 active, not recruiting
Australian and New Zealand Urogenital and Prostate Cancer Trials Group click here
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)  Avelumab (MSB0010718C), Axitinib (AG-013736)  I
 active, not recruiting
Pfizer click here
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer  Axitinib, MK-3475  I
 completed
Pfizer click here
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery  Nivolumab, Ipilimumab, Bevacizumab  
 active, not recruiting
M.D. Anderson Cancer Center click here

Second line treatment (for patients who have had only one prior systemic therapy)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)  Everolimus  III
 active, not recruiting
Bristol-Myers Squibb click here
Savolitinib vs. Sunitinib in MET-driven PRCC  Sunitinib, Savolitinib  III
 active, not recruiting
AstraZeneca click here
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)  Nivolumab, Ipilimumab  II
 active, not recruiting
Australian and New Zealand Urogenital and Prostate Cancer Trials Group click here
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800)  Nivolumab, Ipilimumab  II
 active, not recruiting
Bristol-Myers Squibb click here
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer  Cabozantinib, Sunitinib, Savolitinib, Cabozantinib S-malate, Crizotinib, Sunitinib Malate  II
 recruiting
National Cancer Institute (NCI) click here
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma  Axitinib, X4P-001  I, II
 active, not recruiting
X4 Pharmaceuticals click here
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  Lenvatinib, Pembrolizumab  I, II
 recruiting
Eisai Inc. click here
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:  Bevacizumab, MK-3475  I, II
 active, not recruiting
Arkadiusz Z. Dudek, MD click here
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)  MK-3475, INCB024360  I, II
 active, not recruiting
Incyte Corporation click here
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)  Ipilimumab, Pembrolizumab, Pegylated IFN-alpha 2b  I, II
 active, not recruiting
Merck Sharp & Dohme Corp. click here
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma  Pazopanib + interferon alpha 2A  I, II
 active, not recruiting
Spanish Oncology Genito-Urinary Group click here
Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors  Cabozantinib, Cabozantinib S-malate  I
 recruiting
National Cancer Institute (NCI) click here
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors  Ipilimumab, Atezolizumab, Obinutuzumab, Bevacizumab, Interferon alfa-2b, PEG-interferon alfa-2a  I
 active, not recruiting
Hoffmann-La Roche click here
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery  Nivolumab, Ipilimumab, Bevacizumab  
 active, not recruiting
M.D. Anderson Cancer Center click here

Third line treatment (for patients who have had up to two prior systemic therapies)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)  Everolimus  III
 active, not recruiting
Bristol-Myers Squibb click here
Savolitinib vs. Sunitinib in MET-driven PRCC  Sunitinib, Savolitinib  III
 active, not recruiting
AstraZeneca click here
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)  Nivolumab, Ipilimumab  II
 active, not recruiting
Australian and New Zealand Urogenital and Prostate Cancer Trials Group click here
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800)  Nivolumab, Ipilimumab  II
 active, not recruiting
Bristol-Myers Squibb click here
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma  Axitinib, X4P-001  I, II
 active, not recruiting
X4 Pharmaceuticals click here
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  Lenvatinib, Pembrolizumab  I, II
 recruiting
Eisai Inc. click here
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:  Bevacizumab, MK-3475  I, II
 active, not recruiting
Arkadiusz Z. Dudek, MD click here
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)  MK-3475, INCB024360  I, II
 active, not recruiting
Incyte Corporation click here
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma  Pazopanib + interferon alpha 2A  I, II
 active, not recruiting
Spanish Oncology Genito-Urinary Group click here
Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors  Cabozantinib, Cabozantinib S-malate  I
 recruiting
National Cancer Institute (NCI) click here
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors  Ipilimumab, Atezolizumab, Obinutuzumab, Bevacizumab, Interferon alfa-2b, PEG-interferon alfa-2a  I
 active, not recruiting
Hoffmann-La Roche click here
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery  Nivolumab, Ipilimumab, Bevacizumab  
 active, not recruiting
M.D. Anderson Cancer Center click here